| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17127 R71753 |
Delteil - Beta-blockers, 2024 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: Only chronic indication (hypertension or cardiac) | 1.54 [1.08;2.13] | 36/974 4,054/165,775 | 4,090 | 974 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13539 R54081 |
Bateman_Nordic - Beta-blockers, 2018 | Major congenital malformations (ICD-9: 740.xx-759.xx; ICD-10: Q00.0-Q89.9 (except Q17.0, Q38.1, Q53, Q65.0-Q65.6, Q82.5, Q86)) | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.22 [0.88;1.71] | 48/682 152/2,895 | 200 | 682 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13791 R54088 |
Bateman_USMAX - Beta-blockers, 2018 | Major congenital malformations (ICD-9: 740.xx-759.xx; ICD-10: Q00.0-Q89.9 (except Q17.0, Q38.1, Q53, Q65.0-Q65.6, Q82.5, Q86)) | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.01 [0.80;1.27] | 78/1,668 534/13,232 | 612 | 1,668 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13809 R54309 |
Hoeltzenbein c - Bisoprolol, 2018 | Major birth defects | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 0.77 [0.34;1.75] | 10/294 28/611 | 38 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13935 R54558 |
Vasilakis-Scaramozza - Beta-blockers, 2013 | Any anomaly, excluding minor and chromosomal anomalies | 1st trimester | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.40 [0.60;3.20] | 6/214 16/682 | 22 | 214 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13474 R51971 |
Nakhai-Pour - Beta-blockers, 2010 | Major malformations | 1st trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.99 [0.31;3.20] C | 3/43 4,152/58,990 | 4,155 | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13584 R52672 |
Queisser-Luft - Beta-blockers, 1996 | Major malformations | throughout pregnancy | nested case control | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.10 [0.30;3.40] | -/- 1,481/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14027 R55137 |
Rosenfeld - Pindolol, 1986 | Major malformations | during pregnancy (anytime or not specified) excluded | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified |
0.17 [0.01;3.83] C excluded (exposition period) |
0/23 2/22 | 2 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 1.16 [0.99;1.35] | 9,117 | 3,875 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asymetry test p-value = 0.9935 (by Egger's regression)
slope=0.1454 (0.1575); intercept=-0.0064 (0.7453); t=0.0085; p=0.9935
excluded